# US 2024/0197687 A1 · Methods of treating neuroinflammation and inhibiting monoamine oxidase-a and restoring/upregulating/increasing il-13 and and pgc-1 by administering oral dosage form containing micronized and nonmicronized particulate metaxalone, alginic acid and propylene glycol alginate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197687 A1
- Document ID: US20240197687A1
- Status: Published application
- Kind: A1
- Application number: 18/215,170
- Filed: 2023-06-28
- Published: 2024-06-20
- Earliest claimed: 2022-07-02
- Assignees: Primus Pharmaceuticals, Inc.
- Applicants: Primus Pharmaceuticals, Inc.
- Inventors: Francesco Squadrito; James C. Lukban; Ryan E. Hartung; Garrett A. Campbell
- Web page: https://patentgrep.com/patent/US20240197687A1

## CPC

- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61P 25/02: for peripheral neuropathies
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of neuroinflammation and conditions associated therewith including chronic and acute conditions as well as specific and non-specific conditions. Oral dosage forms containing 640 mg micronized and non-micronized particulate metaxalone and excipients including alginic acid and propylene glycol alginate. The method includes inhibiting the monoamine oxidase A (MAO-A) enzyme as well as restoring/upregulating/increasing IL-13 and PGC-1α. The treated conditions, among others, include diabetic neuropathy, fibromyalgia, back pain, chronic pain induced depression, restless leg syndrome, anxiety, mood disorder, peripheral neuropathy, and herpetic neuralgia. The method further includes inducing or restoring homeostasis, restoring oxidative homeostasis, restoring basal phenotype from a neuroinflammatory state and improving neuroplasticity.

## Claims

### Claim 1

A method of treating chronic or acute conditions associated with specific or non-specific neuroinflammation in a human consisting of inhibiting the MAO-A isoform enzymatic pathway by administering an oral dosage form comprising:
a therapeutic dose of first and second particulate metaxalones in one or more suitable forms selected from salts, co-crystals, solvates, free form, enantiomers, and polymorphs thereof, and,
one or more pharmaceutically suitable excipients, wherein the dosage form has a stable dissolution profile over time.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

A method of restoring or increasing IL-13 and inhibiting STAT3 consisting of administering an oral dosage form comprising:
a therapeutic dose of first and second particulate metaxalones in one or more suitable forms selected from salts, co-crystals, solvates, free form, enantiomers, and polymorphs thereof, and,
one or more pharmaceutically suitable excipients, wherein the dosage form has a stable dissolution profile over time.

### Claim 5 (depends on 4)

The method of claim 4, further consisting of increasing white matter growth and development in the central nervous system by increasing and/or attenuating the natural pathways responsible for proper white matter cellular growth and repair.

### Claim 6 (depends on 5)

The method of claim 5, further consisting of treating demyelination disorders or diseases.

### Claim 7

A method of increasing or restoring PGC-1α consisting of administering an oral dosage form comprising:
a therapeutic dose of first and second particulate metaxalones in one or more suitable forms selected from salts, co-crystals, solvates, free form, enantiomers, and polymorphs thereof, and,
one or more pharmaceutically suitable excipients, wherein the dosage form has a stable dissolution profile over time.

### Claim 8 (depends on 7)

The method of claim 7, further consisting of treating one or more disorders or diseases selected from sciatica, fibromyalgia, neuropathic pain, ischemic stroke and traumatic brain injury.

### Claim 9 (depends on 8)

The method of claim 8, wherein said neuropathic pain is selected from mechanical allodynia, thermal hyperalgesia, diabetic neuropathy, chemotherapy neuropathy and post-operative pain.

### Claim 10 (depends on 7)

The method of claim 7, further consisting of restoring mitochondrial biogenesis.

### Claim 11 (depends on 7)

The method of claim 7, further consisting of stimulating NRF-1 and NRF-2.

### Claim 12 (depends on 7)

The method of claim 7, further consisting of preventing chronification of neuropathic pain due to haploinsufficiency.

### Claim 13 (depends on 7)

The method of claim 7, further consisting of stimulating AMPK.

### Claim 14 (depends on 13)

The method of claim 13, further consisting of bolstering gene expression and protein syntheses of MnSOD and catalase.

### Claim 15 (depends on 13)

The method of claim 13, further consisting of treating cardiovascular disorder or disease and treating vascular leakage caused by permeability.

### Claim 16 (depends on 7)

The method of claim 7, further consisting of treating pain caused by nerve injury.

### Claim 17 (depends on 7)

The method of claim 7, further consisting of preventing pain chronification caused by burn injury.

### Claim 18

(canceled)

### Claim 19 (depends on 7)

The method of claim 7, further consisting of inhibiting NF-κB.

### Claim 20 (depends on 7)

The method of claim 7, further consisting of revitalizing muscle strength.

### Claim 21 (depends on 7)

The method of claim 7, further consisting of initiating regeneration of muscular tissue.

### Claim 22 (depends on 7)

The method of claim 7, further consisting of promoting an antifibrotic state.

### Claim at position 23

23-47. (canceled)
